stockportfolio.pro
Stocks / AMRX vs CRSP
AMRX vs CRSP
Amneal Pharmaceuticals, Inc. and CRISPR Therapeutics AG side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Amneal Pharmaceuticals, Inc. (AMRX) | CRISPR Therapeutics AG (CRSP) | |
|---|---|---|
| Market cap | $4.9B | $4.9B |
| Revenue (latest FY) | $3.02B | $3.51M |
| Net income (latest FY) | $72.06M | $-581.60M |
| Revenue growth (5y CAGR) | 8.7% | 37.3% |
| Net margin | 2.4% | -16569.8% |
| Return on equity | -101.8% | -30.3% |
| P/E ratio | 41.3 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 3 | 2 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open AMRX — free Open CRSP — freeFrequently asked questions
Which is bigger, AMRX or CRSP?
CRISPR Therapeutics AG is larger by market capitalization — $4.9B versus $4.9B.
Which grows faster, AMRX or CRSP?
Over the last five fiscal years, CRISPR Therapeutics AG grew revenue faster — 37.3%/yr versus 8.7%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.